These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8462179)

  • 1. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia.
    Bercovich D; Friedlander Y; Korem S; Houminer A; Hoffman A; Kleinberg L; Shochat C; Leitersdorf E; Meiner V
    Atherosclerosis; 2006 Mar; 185(1):97-107. PubMed ID: 16002074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia.
    Leitersdorf E
    Drugs; 1994; 47 Suppl 2():54-8. PubMed ID: 7517834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.
    Assouline L; Levy E; Feoli-Fonseca JC; Godbout C; Lambert M
    Pediatrics; 1995 Aug; 96(2 Pt 1):239-46. PubMed ID: 7630677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
    Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
    Sposito AC; Gonbert S; Bruckert E; Atassi M; Beucler I; Amsellem S; Khallouf O; Benlian P; Turpin G
    Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2078-82. PubMed ID: 14512370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.
    Raungaard B; Brorholt-Petersen JU; Jensen HK; Faergeman O
    J Clin Pharmacol; 2000 Apr; 40(4):421-9. PubMed ID: 10761170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.